Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells

Leukemia

Volumn 15, Issue 6, 2001, Pages 936-941

  Blagosklonny, M V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Caspases; Flavopiridol; Leukemia; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; CASPASE INHIBITOR; CYCLOSPORIN A; DOXORUBICIN; EPOTHILONE B; FLAVOPIRIDOL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; N ACETYLLEUCYLLEUCYLNORLEUCINAL; PEPTIDE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL KILLING; CELL NUCLEUS; CELL PROTECTION; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TOXICITY; ERADICATION THERAPY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TUMOR CELL; TUMOR RESISTANCE;

EID: 0034988902     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402127     Document Type: Article

References (37)

1. Apoptosis as a goal of cancer therapy
2. Apoptosis in cancer therapy: Crossing the threshold
3. P53, cell cycle control and apoptosis: Implications for cancer
4. Apoptosis and the dilemma of cancer chemotherapy
5. Apoptosis and therapy
6. Apoptosis and cancer drug targeting
7. Dysregulation of apoptosis in cancer
8. Apoptosis in cancer
9. Caspases: Enemies within
10. The most unkindest cut of all: On the multiple roles of mammalian caspases
11. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
12. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
13. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
14. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes
15. Protease inhibitor-induced apoptosis: Accumulation wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
16. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
17. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell carcinomas
18. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
19. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
20. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
21. Peptide transport by the multidrug resistance pump
22. Drug-resistance enables selective killing of resistant leukemia cells: Exploiting of drug resistance instead of reversal
23. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells
24. Characterization of a human myeloid-leukemia cell line highly resistant to taxol
25. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel
26. Bcl-2 independence of flavopiridol-induced apoptosis
27. A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis
28. Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells
29. Different subcellular distribution of caspase-3 and caspase-7 following Fas-induced apoptosis in mouse liver
30. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor
31. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage
32. Prevention of lymphocyte cell death in sepsis improves survival in mice
33. Neuroprotection by a caspase inhibitor in acute bacterial meningitis
34. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
35. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials
36. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
37. Expression and activity of P-glyco-protein, a multidrug efflux pump, in human hematopoietic stem cells